Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Decitabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 known ✓ | P26358 | 6/20 | 0.80 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.80 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | GMNN | O75496 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | THPO | P40225 | 1/20 | 0.51 |
| ▸ | MTOR | P42345 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | HBB | P68871 | 1/20 | 0.51 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.51 |
| ▸ | PNP | P00491 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | PIM1 | P11309 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Decitabine SCHEMBL3396354 | 0.94 | DNMT1 (0.87) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL3394324 | 0.93 | DNMT1 (0.75) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL3393823 | 0.93 | DNMT1 (0.85) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL3394115 | 0.91 | DNMT1 (0.89) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL20772029 | 0.90 | DNMT1 (0.97) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL20769771 | 0.89 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL117721 | 0.89 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL20651628 | 0.89 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL12800474 | 0.89 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL661233 | 0.89 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100062992-A1 | Salts of 5-Azacytidine | SUPERGEN, INC. (US) | 2010-03-11 | — | — | US | disclosed |
| EP-1793675-A2 | SALTS OF DECITABINE | SuperGen, Inc. (US) | 2007-06-13 | — | — | EP | disclosed |
| EP-1788874-A2 | SALTS OF 5-AZACYTIDINE | SuperGen, Inc. (US) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006037024-A2 | SALTS OF DECITABINE | SUPERGEN, INC. (US) | 2006-04-06 | — | — | WO | disclosed |
| US-20060074046-A1 | Oral administration of decitabine salt | SUPERGEN, INC. | 2006-04-06 | — | — | US | disclosed |
| WO-2006034154-A2 | SALTS OF 5-AZACYTIDINE | SUPERGEN, INC. (US) | 2006-03-30 | — | — | WO | disclosed |
| US-20060069060-A1 | Salts of decitabine | SUPERGEN, INC. | 2006-03-30 | — | — | US | disclosed |
| US-20060063735-A1 | Salts of 5-azacytidine | SUPERGEN, INC. (US) | 2006-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074046-A1 | Oral administration of decitabine salt | DNMT3A, TET2, TET3 | DNMT1 5/4885ADRB1 4217/4885LMNA 2871/4885 |
| US-20100062992-A1 | Salts of 5-Azacytidine | AZI2, TET2, DNMT3A | DNMT1 4/4885ADRB1 4281/4885LMNA 3648/4885 |
| US-20060069060-A1 | Salts of decitabine | DNMT3A, TET2, DNMT1 | DNMT1 3/4885ADRB1 4545/4885LMNA 2268/4885 |
| US-20060063735-A1 | Salts of 5-azacytidine | AZI2, TET2, DNMT3A | DNMT1 4/4885ADRB1 4281/4885LMNA 3648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.